Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 5 ans
A randomized, double-blind, multi-center comparison of the efficacy and safety of certoparin (3000 U anti-Xa o.d.) with unfractionated heparin (5000 IU t.i.d.) in the prophylaxis of thromboembolic events in acutely ill medical patients
The primary objective is to confirm that certoparin is non-inferior in preventing the primary endpoint consisting of proximal deep vein thrombosis (DVT), symptomatic non-fatal pulmonary embolism (PE) ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A multi-center study to assess the safety, effectiveness and tolerance of a study drug FTY720 in patients with certain types of the eye disease uveitis (inflammation in the back of the eye)
To assess the effect of FTY720 on vitreous haze at Day 8 in patients with acute noninfectious posterior, intermediate, or pan uveitis
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 5 ans
A randomized, rater-blinded cross-over multicenter study comparing the clinical efficacy of Ritalin® LA (methylphenidate) treatment (20 or 40 mg orally o.d.) in children with ADHD under different breakfast conditions over two weeks
To demonstrate that Ritalin® LA has comparable efficacy after a very light breakfast compared to a standard continental breakfast in children with ADHD after treatment for one week assessed by weekly ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals Corporation
Update Il y a 5 ans
A study of the Palatability and Tolerability of Exjade Taken with Meals, with Different Liquids or Crushed and Added to Food
To evaluate the palatability of Exjade administered with meals, added to different liquids and crushed and added to food
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 5 ans
A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multiple sclerosis followed by a 1-year open-label treatment phase
To demonstrate that zoledronic acid has superior efficacy compared with placebo on the percent change of bone mineral density (BMD) as assessed by the T-score at lumbar spine and total hip region at m...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma S.A.S
Update Il y a 5 ans
Etude prospective, randomisée, comparant les profils glycémiques sur 72 hr obtenus par enregistrement continu du glucose (CSGM) chez des patients diabétiques de type 2 insuffisamment contrôlés par la metformine en monothérapie, après 8 semaines de traitement adjuvant par Galvus® (vildagliptine) ou Januvia® (sitagliptine)
L’objectif principal est de comparer le profil glycémique nycthéméral obtenu sur 72 heures chez des patients diabétiques de type 2 insuffisamment contrôlés sous metformine seule, après 8 semaines de t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer
To determine the activity of EPO906 administered once every 3 weeks to patients with advanced NSCLC
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 5 ans
Étude JULIET : étude de phase 2 non-randomisée visant à évaluer l’efficacité et la sécurité d’emploi du CTL019 chez des patients ayant un lymphome diffus à grandes cellules B récurrent ou réfractaire. [essai clos aux inclusions]
Le lymphome diffus à grandes cellules B est le type de lymphome non hodgkinien le plus fréquent et il affecte surtout des patients de plus de 60 ans et plus fréquemment les hommes. Les cellules du lym...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Immunothérapie - Vaccinothérapie
,
Thérapie Cellulaire
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Phase I/Ib study of GWN323 alone and in combination with PDR001 in patients with advanced malignancies and lymphomas Estudio de fase I/Ib de GWN323 (anti-GITR) en monoterapia y en combinación con PDR001 (anti-PD-1) en pacientes con tumores sólidos avanzados y linfomas
The purpose of this trial is to explore the clinical utility of two investigational antibodies in patients with advanced cancer or lymphomas. The dose escalation parts will estimate the MTD and/or RD...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Pharmacogenetic analysis study of hepatitis C patients treated with DEB025/Alisporivir alone or with Peg-IFN2a and/or Ribavirin
To assess the impact of potential markers (or polymorphisms) in host genes from patients in studies DEB-025-103, DEB-025-HCV-203 and DEB-025-HCV-205 on the PK profile, safety, and efficacy of alispori...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
22
23
24
25
26
27
28
29
30
31
Next